RTP Mobile Logo

Friday, June 1, 2018, Chicago, IL, 7:00 PM – 9:00 PM

Cases from the Community: Clinical Investigators Provide Their Perspectives on Emerging Research and Actual Patients with Non-Small Cell Lung Cancer

Event Details

Location:
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Time:
6:30 PM – 7:00 PM (Central Time) — Registration and Dinner Buffet
7:00 PM – 9:00 PM (Central Time) — Educational Meeting

Meeting Room:
Grand Ballroom (Level 2)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
 
Faculty:
Matthew D Hellmann, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York

Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Vice Chair, Radiation Therapy Oncology Group
Philadelphia, Pennsylvania

Geoffrey R Oxnard, MD
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Martin Reck, MD, PhD
Head of Department of Thoracic Oncology
Head of Clinical Trial Department
LungenClinic Grosshansdorf
Grosshansdorf, Germany

Alice Shaw, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Center for Thoracic Cancers
Massachusetts General Hospital
Boston, Massachusetts

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology and Takeda Oncology.

Agenda

6:30 PM – 7:00 PM — Registration and Dinner Buffet
7:00 PM – 9:00 PM — Educational Meeting

This CME symposium will focus on the discussion of patients with non-small cell lung cancer (NSCLC) in the care of practicing oncologists in the community setting. Five renowned investigators will serve as the faculty for the event, which will be divided into 5 topic modules each focused on a distinct area of NSCLC management. Each module will feature a faculty-led review of emerging research and case-based discussion designed to demonstrate the optimal application of the data presented to contemporary patient care. To cultivate an interactive experience and maintain audience interest, clinician attendees will use iPads® to complete a premeeting survey related to the cases and topics selected for discussion. The results will be displayed throughout the event to foster additional debate and elucidate any knowledge and/or practice gaps among those in attendance. Attendees will also use the iPads to submit their own questions directly to the moderator or faculty.

A detailed agenda will be made available in the coming weeks.

CE Information

Target Audience:
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).

Learning Objectives and Goals:
At the conclusion of this activity, participants should be able to:

  • Appraise emerging research data documenting the benefits and risks of sequential anti-PD-L1 antibody therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy.
  • Recognize available and emerging research information validating the utility of diagnostic assays designed to measure EGFR, ALK, ROS1, BRAF and PD-L1 status, assess which testing platforms should be used and appropriately employ the results of these assessments to individualize first- and later-line therapy for patients with metastatic NSCLC based on their potential response (or lack thereof) to a specific treatment.
  • Recall the results from the recently presented Phase III FLAURA trial evaluating the role of osimertinib versus gefitinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC, and consider how, if at all, these findings may affect current or future clinical practice.
  • Communicate the efficacy and safety of approved and investigational ALK inhibitors to appropriate patients with NSCLC, considering the predictive utility of ALK mutation testing.
  • Recognize the unique mechanism of action of, available clinical trial data with and indications for the use of dabrafenib with trametinib for BRAF-positive metastatic NSCLC, and use this information to guide nonresearch treatment planning.
  • Consider age, performance status, PD-L1 tumor proportion score and other patient- or disease-related factors to guide the selection of induction and maintenance systemic therapy for metastatic NSCLC without an identifiable driver mutation.
  • Review published research data documenting the safety and efficacy of anti-PD-1 antibodies used as monotherapy or in combination with chemotherapy for newly diagnosed metastatic NSCLC.
  • Describe ongoing trials evaluating novel applications of immune checkpoint inhibitors alone or in combination with other systemic approaches (eg, anti-PD-1/PD-L1 antibodies in combination with other checkpoint inhibitors, chemotherapy or targeted therapy) for diverse lung cancer variants, and counsel appropriately selected patients about participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology and Takeda Oncology.

Location

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

Directions:
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 

Registration

This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.